Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime



Mohammadi F1 ; Narimani M2 ; Esmaeil N3 ; Yousefi H1 ; Eskandarian A1 ; Hejazi SH1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Parasitology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Central Laboratory, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Journal of Isfahan Medical School Published:2012

Abstract

Background: It is necessary to recognize the role and function of immune system in wound healing, control, and treatment of cutaneous leishmaniasis (CL). According to the published papers, immune system factors such of monocyte chemotactic protein-1 (MCP1) and nitric oxide (NO) have an impact on wound healing. In this study, the role of these factors on wound healing and their interaction with glucantime in CL patients were investigated. Methods: In a cross-sectional study, 44 (38 males and 6 females) patients who referred to Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, were diagnosed as positive CL using direct microscopy. Before and after treatment with glucantime, 5 ml whole blood samples were obtained from all samples and the sera were incubated at -70°C until use. Serum levels of MCP1 and NO were determined by enzyme-linked immunosorbent assay (ELISA) method and Grise reaction, respectively. Paired t-test was used to compare NO and MCP1 values before and after treatment. Findings: Improvements in cutaneous lesions and significant elevations in MCP1 and NO levels (P < 0.05) were observed after treatment. These findings show a significant association between treatment with glucantime and levels of NO and MCP1 (P < 0.05). Conclusion: The interesting results of this investigation revealed that MCP1 and NO play an important role in wound healing of patients with CL.
Related Docs
View other Related Docs
1. Serum Monocyte Chemotactic Protein-1 and Nitric Oxide in Cutaneous Leishmaniasis Patients Before and After Treatment With Glucantime, Journal of Isfahan Medical School (2012)
2. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
3. Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2014)
4. Cutaneous Leishmaniasis Reinfection: Skin Disease and Leishmaniasis Research Center, Isfahan, Iran, Journal of Isfahan Medical School (2015)
5. Evaluation of Il-12Rb1, Il-12B, Cxcr-3 and Il-17A Expression in Cases Affected by a Non-Healing Form of Cutaneous Leishmaniasis: An Observational Study Design, BMJ Open (2017)
6. The Comparison of the Ifn-ɤ, Tnf-Α and Il-10 Cytokines in Healing and Non-Healing Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2021)
7. A Comparison of the Effects of Topical Injection of Glucantime Plus Glycolic Acid 70% and Salicylic Acid 20% With Topical Injection of Glucantime Alone in the Treatment of Acute Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2017)
8. Successful Treatment of Lupoid Cutaneous Leishmaniasis With Glucantime and Topical Trichloroacetic Acid (A Case Report), Korean Journal of Parasitology (2008)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (53)
Ali Asilian (16)
Other Related Docs
9. The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2012)
10. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
11. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
12. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
13. Tlr2 and Tlr4 in Cutaneous Leishmaniasis Caused by Leishmania Major, Scandinavian Journal of Immunology (2013)
14. Il-23 and Il-27 Levels in Macrophages Collected From Peripheral Blood of Patients With Healing Vs Non-Healing Form of Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
15. Comparison of Pro-Inflammatory Cytokines of Non-Healing and Healing Cutaneous Leishmaniasis, Scandinavian Journal of Immunology (2017)
16. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Carbon Dioxide Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Dermatology Research and Practice (2016)
17. Exposure to Leishmania Major Modulates the Proportion of Cd4+ T Cells Without Affecting Cellular Immune Responses, Microbiology and Immunology (2007)
18. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
19. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2012)
20. Isolation of Bacteria Causing Secondary Bacterial Infection in the Lesions of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2008)
21. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
22. Comparative Effect of Topical Trichloroacetic Acid and Intralesional Meglumine Antimoniate in the Treatment of Acute Cutaneous Leishmaniasis, International Journal of Pharmacology (2006)
23. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
24. Identification of Leishmania Isolates From Healing and Nonhealing Cutaneous Leishmaniasis Patients Using Internal Transcribed Spacer Region Pcr, Jundishapur Journal of Microbiology (2014)
25. Effect of Topical Honey Application Along With Intralesional Injection of Glucantime in the Treatment of Cutaneous Leishmaniasis, BMC Complementary and Alternative Medicine (2007)
26. The Skin Side Effects of Topical Glucantime in Patients With Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2015)
27. A Comparison Between the Effects of Glucantime, Topical Trichloroacetic Acid 50% Plus Glucantime, and Fractional Laser Plus Glucantime on Cutaneous Leishmaniasis Lesions, Journal of Isfahan Medical School (2013)
28. The Efficacy of 5% Trichloroacetic Acid Cream in the Treatment of Cutaneous Leishmaniasis Lesions, Journal of Dermatological Treatment (2012)
29. Electrocardiographic Changes in Patients With Cutaneous Leishmaniasis Treated With Systemic Glucantime, Annals of the Academy of Medicine Singapore (2008)
30. Topical Effectiveness of Different Concentrations of Nanosilver Solution on Leishmania Major Lesions in Balb/C Mice, Journal of Vector Borne Diseases (2012)
31. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Isfahan Medical School (2014)
32. The Effect of Intralesional Meglumine Antimoniate (Glucantime) Versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions, Journal of Research in Medical Sciences (2012)
33. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)
34. Distribution Frequency of Pathogenic Bacteria Isolated From Cutaneus Leishmaniasis Lesions, Korean Journal of Parasitology (2008)
35. Study of Il-12 Agonists in Macrophages From Patients With Healing and Non-Healing Forms of Cutaneous Leishmaniasis, Journal of Isfahan Medical School (2013)
36. Comparison of Protein Profile of Killed and Autoclaved Leishmania Major Using Polyacrylamide Gel Electrophoresis, Journal of Isfahan Medical School (2013)
37. Reevaluating Leishmanin Skin Test As a Marker for Immunity Against Cutaneous Leishmaniasis, International Journal of Dermatology (2013)
38. Comparison Between the Efficacy of Photodynamic Therapy and Topical Paromomycin in the Treatment of Old World Cutaneous Leishmaniasis: A Placebo-Controlled, Randomized Clinical Trial, Journal of Isfahan Medical School (2012)
39. Efficacy of Adjunctive Topical Liposomal Clarithromycin on Systemic Glucantime in Old World Cutaneous Leishmaniasis: A Pilot Clinical Study, Frontiers in Pharmacology (2023)
40. Treatment of Cutaneous Leishmaniasis With Ketoconazole Cream, Journal of Dermatological Treatment (2003)
41. Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask, Journal of Isfahan Medical School (2013)
42. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
43. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
44. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
45. Recombinant C-Reactive Protein: A Potential Candidate for the Treatment of Cutaneous Leishmaniasis of Balb/C Mice Caused by Leishmania Major, Acta Parasitologica (2021)
46. Identification of Leishmania Species and Treatment Courses in Patients With Leishmaniasis in Isfahan, Iran, Journal of Isfahan Medical School (2012)
47. Aquaglyceroporin1 Gene Expression in Antimony Resistance and Susceptible Leishmania Major Isolates, Journal of Vector Borne Diseases (2016)
48. Comparative Study of the Efficacy of Combined Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Vs. Cryotherapy and Intralesional Meglumine Antimoniate (Glucantime®) Alone for the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2004)
49. The Comparison Between Trichloroacetic Acid 50% and Co2 Laser in the Treatment of Cutaneous Leishmaniasis Scar, Indian Journal of Dermatology (2011)
50. Comparison of Healing Effects of Local Injection of Glucantime With or Without Trichloroacetic Acid 50% in Cutaneous Leshmaniasis, Journal of Isfahan Medical School (2009)